## Murat Kazim Ersanli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8065628/publications.pdf

Version: 2024-02-01

60 papers 5,909 citations

257357 24 h-index 54 g-index

63 all docs

63 docs citations

63 times ranked 7647 citing authors

#	Article	IF	CITATIONS
1	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. New England Journal of Medicine, 2018, 379, 2097-2107.	13.9	2,211
2	Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. New England Journal of Medicine, 2015, 372, 1791-1800.	13.9	1,585
3	Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. European Heart Journal, 2016, 37, 2882-2889.	1.0	222
4	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 618-628.	5.5	207
5	Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart, 2017, 103, 307-314.	1.2	205
6	Alirocumab in Patients With Polyvascular Disease and Recent Acute CoronaryÂSyndrome. Journal of the American College of Cardiology, 2019, 74, 1167-1176.	1.2	154
7	Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events. Journal of the American College of Cardiology, 2019, 73, 387-396.	1.2	131
8	Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. PLoS ONE, 2016, 11, e0164076.	1.1	118
9	Effect of Alirocumab on Mortality After Acute Coronary Syndromes. Circulation, 2019, 140, 103-112.	1.6	107
10	Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open, 2017, 7, e017157.	0.8	92
11	Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. PLoS ONE, 2018, 13, e0191592.	1.1	80
12	Does Sex Affect Anticoagulant Use for Stroke Prevention in Nonvalvular Atrial Fibrillation?. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, S12-20.	0.9	74
13	Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry. International Journal of Cardiology, 2016, 223, 543-547.	0.8	71
14	Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation. Circulation, 2019, 139, 787-798.	1.6	60
15	Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. European Heart Journal, 2019, 40, 2801-2809.	1.0	45
16	Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. American Heart Journal, 2019, 213, 35-46.	1.2	45
17	The Relationship Between Chronic Kidney Disease and SYNTAX Score. Angiology, 2011, 62, 504-508.	0.8	44
18	Management and 1‥ear Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELDâ€AF Registry. Journal of the American Heart Association, 2019, 8, e010510.	1.6	44

#	Article	lF	Citations
19	Platelet-to-Lymphocyte Ratio Predicts Contrast-Induced Nephropathy in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. Angiology, 2015, 66, 964-968.	0.8	35
20	Long-Term Follow-Up of Patients at High Risk for Nephropathy After Contrast Exposure. Angiology, 2015, 66, 514-518.	0.8	33
21	<i>N</i> â€acetylcysteine versus <i>N</i> â€acetylcysteine + theophylline for the prevention of contrast nephropathy. European Journal of Clinical Investigation, 2009, 39, 793-799.	1.7	31
22	Impact of gender on event rates at 1â€year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. BMJ Open, 2017, 7, e014579.	0.8	30
23	Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. European Heart Journal, 2018, 39, 464-473.	1.0	28
24	Evolving quality standards for large-scale registries: the GARFIELD-AF experience. European Heart Journal Quality of Care & Care	1.8	27
25	Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation. JAMA Cardiology, 2019, 4, 526.	3.0	26
26	The Effect of Exercise to P Wave Dispersion and Its Evaluation as a Predictor of Atrial Fibrillation. Annals of Noninvasive Electrocardiology, 2003, 8, 308-312.	0.5	18
27	Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. Indian Heart Journal, 2018, 70, 828-835.	0.2	16
28	Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: results from the GARFIELD-AF registry. Acta Cardiologica, 2019, 74, 309-318.	0.3	16
29	Chronic Kidney Disease as a Predictor of Coronary Lesion Morphology. Angiology, 2010, 61, 344-349.	0.8	15
30	Why are outcomes different for registry patients enrolled prospectively and retrospectively? Insights from the global anticoagulant registry in the FIELD-Atrial Fibrillation (GARFIELD-AF). European Heart Journal Quality of Care & Clinical Outcomes, 2018, 4, 27-35.	1.8	15
31	Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELDâ€AF and treated with vitamin K antagonists. British Journal of Haematology, 2016, 174, 610-623.	1.2	13
32	Risk Profile and 1-Year Outcome of Newly Diagnosed Atrial Fibrillation in Japan ― Insights From GARFIELD-AF ―. Circulation Journal, 2018, 83, 67-74.	0.7	12
33	Impact of continuation of metformin prior to elective coronary angiography on acute contrast nephropathy in patients with normal or mildly impaired renal functions. Anatolian Journal of Cardiology, 2017, 18, 334-339.	0.5	12
34	Percutaneous coronary intervention vs. optimal medical therapy - the other side of the coin: medication adherence. Journal of Clinical Pharmacy and Therapeutics, 2013, 38, 476-479.	0.7	11
35	The role of media on statin adherence. International Journal of Cardiology, 2015, 201, 139.	0.8	8
36	Relationship between serum endothelin-1 level and spontaneous reperfusion in patients with acute myocardial infarction. Coronary Artery Disease, 2015, 26, 37-41.	0.3	7

#	Article	IF	Citations
37	Impact of statin non-adherence on in-stent restenosis following bare-metal stent implantation. International Journal of Cardiology, 2016, 203, 529-531.	0.8	7
38	Antithrombotic treatment patterns and stroke prevention in patients with atrial fibrillation in TURKEY: inferences from GARFIELD-AF registry. Anatolian Journal of Cardiology, 2019, 21, 272-280.	0.5	7
39	Increased secretion of insulin during oral glucose tolerance test can be a predictor of stent restenosis in nondiabetic patients. Catheterization and Cardiovascular Interventions, 2003, 58, 306-312.	0.7	6
40	Admission Hyperglycemia and TIMI Frame Count in Primary Percutaneous Coronary Intervention. Angiology, 2012, 63, 325-329.	0.8	6
41	Admission Hyperglycemia Is Associated with Failed Reperfusion Following Fibrinolytic Therapy in Patients with STEMI: Results of a Retrospective Study. American Journal of Cardiovascular Drugs, 2015, 15, 35-42.	1.0	6
42	A Patient With Bicuspid Aorta and Intercoronary Continuity A Rare Variant of Coronary Circulation. International Heart Journal, 2004, 45, 153-155.	0.6	6
43	Comparison of Long-Term Outcomes in Real-World Patients Between Resolute Zotarilumus-Eluting and Paclitaxel-Eluting Stents in Small Vessel. Angiology, 2016, 67, 490-495.	0.8	3
44	P-wave dispersion and its relationship with the severity of the disease in patients with stable coronary artery disease. İstanbul Kuzey Klinikleri, 2014, 1, 65-70.	0.1	3
45	Middle East Treatment Strategies and Clinical Outcomes in Patients with Atrial Fibrillation: One-Year Follow-up Data from Garfield-AF Study. Advances in Therapy, 2021, 38, 2391-2405.	1.3	2
46	A case of renal artery embolism treated by selective intra-arterial infusion of tissue plasminogen activator. Turk Kardiyoloji Dernegi Arsivi, 2013, 41, 534-536.	0.6	2
47	Relationship between myocardial performance index and severity of coronary artery disease in patients with non-ST -segment elevation acute coronary syndrome. Cardiovascular Journal of Africa, 2017, 28, 4-7.	0.2	2
48	Validation of SYNTAX and clinical SYNTAX scores in predicting atrial fibrillation following on-pump coronary artery bypass grafting. Turkish Journal of Thoracic and Cardiovascular Surgery, 2017, 25, 333-339.	0.2	2
49	Dýnya Pulmoner Hipertansiyon Kongresi Yeni Pulmoner Hipertansiyon Tanımlamasının Pre-kapiller Pulmoner Hipertansiyon Prevalansına Etkisi. Turk Kardiyoloji Dernegi Arsivi, 2019, 47, 594-598.	0.6	2
50	A young patient with acute myocardial infarction due to Bonsai treated with glycoprotein Ilbilla inhibitor. Anatolian Journal of Cardiology, 2020, 25, 352-354.	0.5	2
51	Pentraxin-3 a novel biomarker for predicting coronary artery disease. European Heart Journal, 2013, 34, P3108-P3108.	1.0	1
52	Contrast-induced acute kidney injury in patients with non-ST-segment elevation myocardial infarction undergoing early versus delayed invasive strategy. International Journal of Cardiology, 2016, 203, 638-639.	0.8	1
53	Revascularization of chronic coronary artery conclusions using laser debulking followed by stent implantation. Acta Cardiologica, 2003, 58, 149-153.	0.3	1
54	The association of neutrophil to lymphocyte ratio and TIMI frame count in primary percutaneous coronary intervention. Minerva Cardioangiologica, 2019, 67, 471-476.	1.2	1

#	Article	lF	Citations
55	OP-090 THE EFFECT OF ELECTROCARDIOGRAPHIC ISCHEMIA GRADE ON REPERFUSION IN ST-ELEVATION MYOCARDIAL INFARCTION. International Journal of Cardiology, 2010, 140, S26.	0.8	0
56	OP-109 P WAVE DISPERSION IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE AND TO DETERMINE ITS RELATIONSHIP WITH THE SEVERITY OF THE DISEASE. International Journal of Cardiology, 2010, 140, S31.	0.8	0
57	PCI vs Optimal Medical Therapy - The Other Side of the Coin: Medication Adherence. Journal of the American College of Cardiology, 2013, 62, C22.	1.2	0
58	Cardiac Tamponade due to Left Ventricular Pseudoaneurysm After Aortic Valve Replacement. Heart Surgery Forum, 2013, 16, 49.	0.2	0
59	Does Tight Glucose Control During the First 24 hours of Hospitalization Reduce Scintigraphic Infarct Size in STEMI Patients?. International Journal of Cardiovascular Sciences, 2020, , .	0.0	0
60	Author`s Reply. Anatolian Journal of Cardiology, 2018, 19, 155-156.	0.5	0